Clinical trials: Endometrial Carcinoma
Complex Endometrial Hyperplasia With Atypia, Stage IA Uterine Corpus Cancer
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was…
- Conditions
- Complex Endometrial Hyperplasia With Atypia, Stage IA Uterine Corpus Cancer, Stage IB Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT02342730
- Testing
- Weight Loss Specialist, Quality-of-Life Assessment, Medical Chart Review
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Endometrial Cancer
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Patients with advanced mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) endometrial cancer (EC) are currently treated as one entity, and immune checkpoint inhibitor (ICI) monotherapy is the treatment of…
- Trial name
- CAN-RESPOND (NCT05550558)
- Testing
- Anlotinib + Camrelizumab
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumor, NSCLC
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
This is a multicenter, open-label, dose-escalation and efficacy/safety Phase I/II study to assess RP2D, safety, tolerability and anti-tumor activity of Sintilimab + afuresertib + nab-paclitaxel or docetaxel administered as a…
- Conditions
- Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT05383482
- Testing
- Afuresertib, Nab paclitaxel, Docetaxel
- Where
- 5 sites in China
- Volunteers
- 22 people
- Sponsor
- Laekna Limited
Endometrial Cancer, Cervical Stromal Invasion
Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer
Retrospectively collect preoperative transvaginal B-mode ultrasound (BMUS), color Doppler flow imaging (CDFI) and three-dimensional ultrasound (3D-US) images and clinical data in patients with non-endometrial cancer diseases and…
- Conditions
- Endometrial Cancer, Cervical Stromal Invasion, Transvaginal Ultrasound
- Trial name
- NCT05387460
- Testing
- radiomics
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Solid Tumors (Phase 1), HNSCC
MTX-531-001 Phase 1 Study in Advanced Solid Tumors
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors.
- Conditions
- Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer
- Trial name
- NCT07874880
- Testing
- MTX-531
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- MEKanistic Therapeutics, Inc.
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Cancer, Endometrial Cancer
Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer
This study aims at developing an accurate, simple, and cost-effective method for screening and early detection of uterine cancers
- Trial name
- NCT00471120
- Testing
- P2x7 assay
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dick Domanik
Endometrial Cancer
Uterine Manipulator in Endometrial Cancer Surgery: Pro MUCEI Study
The uterine manipulator is a device commonly used in minimally invasive hysterectomy surgery for endometrial cancer. However, without substantial evidence to support its use, surgeons are required to make decisions about its use…
- Trial name
- proMUCEI (NCT05242276)
- Testing
- USE OF UTERINE MANIPULATOR DURING THE HYSTERECTOMY
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Endometrial Cancer
27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery
This study will compare the use of 27-inch and 55-inch endoscopic imaging monitors during minimally invasive surgery for women with endometrial cancer. Participants will be randomly assigned to one of the two monitor groups.
- Trial name
- NCT07882277
- Testing
- 27-Inch Endoscopic Imaging Monitor, 55-Inch Endoscopic Imaging Monitor
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Metehan Uzundal
Endometrial Cancer
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
- Trial name
- NCT06481592
- Testing
- Lifileucel
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Endometrial Cancer, Fallopian Tube Cancer
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004082
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Endometrial Cancer
Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating women who have…
- Trial name
- NCT00005861
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- 10 sites in United States
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Serous Endometrial Intraepithalial Carcinoma, SEIC
Serous Endometrial Intraepithelial Carcinoma (SEIC): Prospective Registration Study
Background: Serous endometrial intra-epithelial carcinoma (SEIC) is a rare condition affecting the lining of the uterus. It's a pre-cancerous change that might lead to cancer if not treated.
- Trial name
- SEIC (NCT06677242)
- Testing
- Blood sample (serum) for circulating tumor DNA and cervical smear for genome-wide methylation sequencing
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Colorectal Cancer, Endometrial Cancer
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
The primary aim of this study is to collect and store data, tissue, and personal and family histories from patients being screened for colorectal cancer and/or endometrial cancer at NYPH and WCM for routine clinical care and to…
- Conditions
- Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes
- Trial name
- NCT06096688
- Where
- United States
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Endometrioid Carcinoma, Clear Cell Carcinoma
Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)
The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma.
- Conditions
- Endometrioid Carcinoma, Clear Cell Carcinoma, Endometriosis
- Trial name
- EAOC (NCT01732432)
- Sponsor
- University Hospital, Basel, Switzerland
Endometrial Cancer
Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer
Hysteroscopic vs. Cervical Injection for Sentinel Node Detection of Endometrial Cancer: a multicenter prospective randomized study
- Trial name
- SLN_EC (NCT04302714)
- Testing
- Hysteroscopic injection, Cervical injection
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Women With Suspected or Confirmed Gynecological Disease
DOvEEgene Fleur: New Uterine Sampling Tool
This study is related to a previous study from the same group which started in 2014 (NTC02288676, McGill REB A08-M79-13B, MUHC REB 2020-5945) to develop a clinically implementable screening test -DovEEgene: developing and…
- Trial name
- NCT04258449
- Testing
- DOvEEgene Fleur Sampling
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.